Reactive Arthritis Or Chronic Infectious Arthritis? J Sibilia, F-X Limbach
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Comparative Genome Analysis of 19 Ureaplasma Urealyticum and Ureaplasma Parvum Strains
Paralanov et al. BMC Microbiology 2012, 12:88 http://www.biomedcentral.com/1471-2180/12/88 RESEARCH ARTICLE Open Access Comparative genome analysis of 19 Ureaplasma urealyticum and Ureaplasma parvum strains Vanya Paralanov1, Jin Lu2, Lynn B Duffy2, Donna M Crabb2, Susmita Shrivastava1, Barbara A Methé1, Jason Inman1, Shibu Yooseph1, Li Xiao2, Gail H Cassell2, Ken B Waites2 and John I Glass1* Abstract Background: Ureaplasma urealyticum (UUR) and Ureaplasma parvum (UPA) are sexually transmitted bacteria among humans implicated in a variety of disease states including but not limited to: nongonococcal urethritis, infertility, adverse pregnancy outcomes, chorioamnionitis, and bronchopulmonary dysplasia in neonates. There are 10 distinct serotypes of UUR and 4 of UPA. Efforts to determine whether difference in pathogenic potential exists at the ureaplasma serovar level have been hampered by limitations of antibody-based typing methods, multiple cross-reactions and poor discriminating capacity in clinical samples containing two or more serovars. Results: We determined the genome sequences of the American Type Culture Collection (ATCC) type strains of all UUR and UPA serovars as well as four clinical isolates of UUR for which we were not able to determine serovar designation. UPA serovars had 0.75−0.78 Mbp genomes and UUR serovars were 0.84−0.95 Mbp. The original classification of ureaplasma isolates into distinct serovars was largely based on differences in the major ureaplasma surface antigen called the multiple banded antigen (MBA) and reactions of human and animal sera to the organisms. Whole genome analysis of the 14 serovars and the 4 clinical isolates showed the mba gene was part of a large superfamily, which is a phase variable gene system, and that some serovars have identical sets of mba genes. -
Roles of Oral Bacteria in Cardiovascular Diseases—From
J Pharmacol Sci 113, 000 – 000 (2010) Journal of Pharmacological Sciences ©2010 The Japanese Pharmacological Society Forum Minireview Roles of Oral Bacteria in Cardiovascular Diseases — From Molecular Mechanisms to Clinical Cases: Implication of Periodontal Diseases in Development of Systemic Diseases Hiroaki Inaba1 and Atsuo Amano1,* 1Department of Oral Frontier Biology, Graduate School of Dentistry, Osaka University, Suita 565-0871, Japan Received November 16, 2009; Accepted December 21, 2009 Abstract. Periodontal diseases, some of the most common infectious diseases seen in humans, are characterized by gingival inflammation, as well as loss of connective tissue and bone from around the roots of the teeth, which leads to eventual tooth exfoliation. In the past decade, the as- sociation of periodontal diseases with the development of systemic diseases has received increas- ing attention. Although a number of studies have presented evidence of close relationships between periodontal and systemic diseases, the majority of findings are limited to epidemiological studies, while the etiological details remain unclear. Nevertheless, a variety of recent hypothesis driven investigations have compiled various results showing that periodontal infection and subsequent direct oral-hematogenous spread of bacteria are implicated inPROOF the development of various systemic diseases. Herein, we present current understanding in regard to the relationship between periodon- tal and systemic diseases, including cardiovascular diseases, preterm delivery of low birth weight, diabetes mellitus, respiratory diseases, and osteoporosis. Keywords: periodontal disease, diabetes mellitus, cardiovascular disease, preterm delivery, Porphyromonas gingivalis, oral bacteria 1. Introduction detected in heart valve lesions and atheromatous plaque (5, 6), amniotic fluid of pregnant women with threatened Epidemiological and interventional studies of humans premature labor (11), and placentas from cases of preterm have revealed close associations between periodontal delivery (12, 13). -
Reactive Arthritis This Sheet Has Been Written for People Affected by Reactive Arthritis
ARTHRIINFORMATIONTI SHEETS ARTHRIINFORMATIONTI SHEETS Reactive arthritis This sheet has been written for people affected by reactive arthritis. It provides general information to help you understand how you may be affected. This sheet also covers how reactive arthritis usually resolves over time. What is reactive arthritis? It is not known why some people who get these Reactive arthritis is a condition that causes infections develop reactive arthritis and some do not. inflammation, pain and swelling of the joints. It usually A certain gene called HLA-B27 is associated with develops after an infection, often in the bowel or genital reactive arthritis, especially inflammation of the spine. areas. The infection causes activity in the immune However this is a perfectly normal gene and there are system. The normal role of your body’s immune system many more people who have this gene and do not get is to fight off infections to keep you healthy. In some reactive arthritis. people this activity of the immune system causes joints to become inflamed, however the joints themselves How is it diagnosed? are not actually infected. About one in 10 people with Your doctor will diagnose reactive arthritis from your specific types of infections will get reactive arthritis. symptoms and a physical examination. Your doctor may also order blood tests for inflammation, such as the What are the symptoms? erythrocyte sedimentation rate (ESR) and C-reactive Reactive arthritis usually begins a few weeks after an protein (CRP) tests. Blood tests may also help to rule infection. Symptoms can affect many parts of the body out other types of arthritis. -
Confidential
CONFIDENTIAL CHILD’S MEDICAL INFORMATION The following is important information about my child’s medical condition and how the condition may affect their ability to fully participate in a regular school setting. The goal is to try to normalize every day school routines/activities while also meeting my child’s unique needs in the least disruptive manner. This document is not intended to replace any existing Individual Educational Plan (IEP) or the 504 Plan, but rather to serve as a supplement or addendum to enhance my child’s education. Medical information will be updated at the beginning of each new school year and throughout the school year as deemed necessary. “We may not look sick, but turn our bodies inside out and they will tell different stories.” Wade Sutherland CHILD’S NAME: ____________________________________________________________________________ ACADEMIC YEAR: _____________________GRADE: __________DOB: __________________AGE: _________ HOME ADDRESS: __________________________________________________________________________ PARENT/LEGAL GUARDIAN: ________________________________________________________________ PARENT/LEGAL GUARDIAN CONTACT NUMBER: ______________________________________________ SCHOOL: ________________________________________________________________________________ EMERGENCY CONTACT (2 PEOPLE) NAME: __________________________________________________________________________________ RELATIONSHIP: ____________________________ PHONE NUMBER: ________________________________ NAME: __________________________________________________________________________________ -
Anaphylaxis During the Perioperative Period
REVIEW ARTICLE Anaphylaxis During the Perioperative Period David L. Hepner, MD*, and Mariana C. Castells, MD, PhD† *Department of Anesthesiology, Perioperative and Pain Medicine, and †Allergy and Clinical Immunology Training Program, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Anesthesiologists use a myriad of drugs during the provi- perioperative period. Symptoms may include all organ sion of an anesthetic. Many of these drugs have side ef- systems and present with bronchospasm and cardiovas- fects that are dose related, and some lead to severe cular collapse in the most severe cases. Management of immune-mediated adverse reactions. Anaphylaxis is the anaphylaxis includes discontinuation of the presumptive most severe immune-mediated reaction; it generally oc- drug (or latex) and anesthetic, aggressive pulmonary and curs on reexposure to a specific antigen and requires the cardiovascular support, and epinephrine. Although a se- release of proinflammatory mediators. Anaphylactoid re- rum tryptase confirms the diagnosis of an anaphylactic actions occur through a direct non-immunoglobulin reaction, the offending drug can be identified by skin- E-mediated release of mediators from mast cells or from prick, intradermal testing, or serologic testing. Prevention complement activation. Muscle relaxants and latex of recurrences is critical to avoid mortality and morbidity. account for most cases of anaphylaxis during the (Anesth Analg 2003;97:1381–95) he term “anaphylaxis” was coined by Nobel reactions in which immune-complex formation and dep- prize recipients Portier and Richet (1) in 1902, osition leads to tissue damage (3). Anaphylactoid reac- T when they described a dog that had tolerated a tions occur through a direct nonimmune-mediated re- previous injection of actinotoxin, a jellyfish toxin, but lease of mediators from mast cells and/or basophils or reacted with bronchial spasm, cardiorespiratory ar- result from direct complement activation, but they rest, and death to a smaller dose 14 days later. -
Reactive Arthritis
PATIENT FACT SHEET Reactive Arthritis Reactive arthritis is an inflammatory disease that Most often, these bacterial infections are in the genitals occurs in reaction to infections by certain bacteria. or bowels, including the sexually transmitted infection Arthritis may show up a month after the infection. Once Chlamydia trachomatis, and bowel infections like called Reiter’s syndrome, it is a “spondyloarthropathy.” Campylobacter, Salmonella, Shigella and Yersinia. Reactive arthritis often affects men between 20 and CONDITION 50. It’s usually short in duration, but can be chronic in some people. DESCRIPTION Reactive arthritis symptoms include pain and swelling discharge from the genitals, but a urine or genital swab in knees, ankles or heels; severe swelling of toes or test can show signs of this infection. Bowel infections fingers; and persistent lower back pain that tends to may cause diarrhea. be more severe at night or in the morning. It may cause Most people with these very common infections irritated, red eyes, burning during urination, or a rash on don’t get reactive arthritis. People who test positive for the palms or soles of the feet. the HLA-B27 gene may be at higher risk for severe or To diagnose reactive arthritis, a rheumatologist may chronic arthritis, but those who test negative may get SIGNS/ look for these symptoms as well as signs of the original reactive arthritis too. People with weakened immune SYMPTOMS infection. Chlamydia may cause watery or pus-like systems from HIV or AIDS may develop reactive arthritis. Effective treatments are available for reactive arthritis. Later-stage, or chronic reactive arthritis, may be It is treated according to how far the disease has treated with disease-modifying antirheumatic drugs progressed. -
Fis-His-2020-Abstract-Supplement-Free-Paper.Pdf
Abstract supplement (free paper abstracts) FIS/HIS International 2020 cannot be held responsible for errors or inconsistencies contained within the abstract supplement. Only major formatting alterations have been made and abstract content remains consistent with what was entered at time of submission by the author/s. How to search this document Laptop, PC or similar: ‘Ctrl’ + ‘F’ or ‘Edit’ then ‘Find’ Smart device: Open this PDF in either the 'iBooks' app (Apple) or 'My Files' app (Android). Both are built in apps and have a magnifying glass search icon. Contents A quick reference guide by topic, paper number and presentation type can be found at the end of the document or click here. (Click paper title to take you straight there) Free paper oral presentations 11: Investigations, actions and learning from an outbreak of SARS-CoV-2 infection among health care workers in the United Kingdom ........................................................................................................................ 13 12: Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care ...................... 14 20: Impact of antibiotic timing on mortality from Gram negative Bacteraemia in an English District General Hospital: the importance of getting it right every time .................................................................................... 15 35: Case report: A fall in the forest ................................................................................................................... 16 65: Not -
Reactive Arthritis Information Booklet
Reactive arthritis Reactive arthritis information booklet Contents What is reactive arthritis? 4 Causes 5 Symptoms 6 Diagnosis 9 Treatment 10 Daily living 16 Diet 18 Complementary treatments 18 How will reactive arthritis affect my future? 19 Research and new developments 20 Glossary 20 We’re the 10 million people living with arthritis. We’re the carers, researchers, health professionals, friends and parents all united in Useful addresses 25 our ambition to ensure that one day, no one will have to live with Where can I find out more? 26 the pain, fatigue and isolation that arthritis causes. Talk to us 27 We understand that every day is different. We know that what works for one person may not help someone else. Our information is a collaboration of experiences, research and facts. We aim to give you everything you need to know about your condition, the treatments available and the many options you can try, so you can make the best and most informed choices for your lifestyle. We’re always happy to hear from you whether it’s with feedback on our information, to share your story, or just to find out more about the work of Versus Arthritis. Contact us at [email protected] Registered office: Versus Arthritis, Copeman House, St Mary’s Gate, Chesterfield S41 7TD Words shown in bold are explained in the glossary on p.20. Registered Charity England and Wales No. 207711, Scotland No. SC041156. Page 2 of 28 Page 3 of 28 Reactive arthritis information booklet What is reactive arthritis? However, some people find it lasts longer and can have random flare-ups years after they first get it. -
Rheumatic Fever and Post-Streptococcal Reactive Arthritis Version of 2016
https://www.printo.it/pediatric-rheumatology/IE/intro Rheumatic Fever And Post-streptococcal Reactive Arthritis Version of 2016 4. POST-STREPTOCOCCAL REACTIVE ARTHRITIS 4.1 What is it? Cases of streptococcal-associated arthritis have been described both in children and young adults. It is usually called "reactive arthritis" or "post-streptococcal reactive arthritis" (PSRA). PSRA commonly affects children between 8 to 14 years of age and young adults between 21 to 27 years. It usually develops within 10 days after a throat infection. If differs from arthritis of acute rheumatic fever (ARF), which mainly involves large joints. In PSRA, large and small joints and the axial skeleton are involved. It usually lasts longer than ARF — about 2 months, sometimes longer. Low grade fever might be present, with abnormal laboratory tests indicating inflammation (C reactive protein and/or erythrocyte sedimentation rate). The inflammatory markers are lower than in ARF. The diagnosis of PSRA relies on arthritis with evidence of recent streptococcal infection, abnormal streptococcal antibody tests (ASO, DNAse B) and the absence of the signs and symptoms in a diagnosis of ARF according to "Jones criteria". PSRA is a different entity to ARF. PSRA patients will probably not develop carditis. Currently, the American Heart Association recommends prophylactic antibiotics for one year after symptoms onset. In addition, these patients should be carefully observed for clinical and echocardiographic evidence of carditis. If heart disease appears, the patient should be treated as in ARF; otherwise prophylaxis can be discontinued. Follow-up with a cardiologist is recommended. 1 / 2 2 / 2 Powered by TCPDF (www.tcpdf.org). -
Reactivation of Inflammatory Monoarthritis During Dupilumab Treatment Used for Prurigo Nodularis
Arch Rheumatol 2022;37(x):i-ii doi: 10.46497/ArchRheumatol.2022.8780 LETTER TO THE EDITOR Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis Ecem Bostan1, Duygu Gülseren1, Zehra Özsoy2, Fatma Bilge Ergen3 1Department of Dermatology, Hacettepe University Faculty of Medicine, Ankara, Turkey 2Department of Internal Diseases, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey 3Department of Radiology, Hacettepe University Faculty of Medicine, Ankara, Turkey Dupilumab is a humanized monoclonal dupilumab. Although her clinical manifestations antibody which specifically targets interleukin-4/ and pruritus improved, she developed mild right interleukin-13 receptor and is primarily indicated for knee swelling, warmness, and arthralgia after the the treatment of atopic dermatitis, although it has first maintenance dose following the loading dose. been shown to be efficacious in various disorders Upon questioning, we recognized that the patient including asthma, chronic rhinosinusitis, prurigo developed reactive arthritis in the right knee, nodularis.1 Herein, we report an extraordinary when she was 10 years old. Until now, she stayed case related to the exacerbation of inflammatory asymptomatic. She was consulted to rheumatology arthritis in a patient under dupilumab treatment department and effusion was detected by right for prurigo nodularis. knee ultrasonography and arthrocentesis was performed which revealed no bacterial growth. An 18-year-old woman with a history of allergic Elevated C-reactive protein and erythrocyte rhinitis and atopic dermatitis, presented for her sedimentation levels were noted. Rheumatological pruritic lesions. The pruritic nodules started from markers were all negative. Right knee magnetic the lumbar area nine years ago and subsequently resonance imaging showed moderate effusion spread to entire body. -
CASEE-2017 Session1b -Eva-Tvrda
A The 8th International CASEE Conference Warsaw University of Life Sciences – SGGW May 14 - 16, 2017 . Decreased sperm quality visible in routine semen analysis: . loss of sperm motility . morphological alterations . acrosome dysfunction . disruption of membrane integrity . oxidative stress . Most data connected to bacterial contamination of ejaculates: well-known causative agents of urogenital tract infections . Escherichia coli, Staphylococcus aureus, Ureaplasma urealyticum, Mycoplasma hominis, Chlamydia trachomatis . Ejaculates collected for reproductive technologies - certain contamination: . semen collection is not an entirely serile process . factors for semen contamination: artifical vaginas, environmental conditions, human factors . Current interest shifts to other bacteria, responsible for the colonization and contamination of the male urogenital tract, rather than infection . Gram-positive, catalase-negative, non-spore-forming, facultative anaerobic bacteria . Lactic acid bacteria (LAB) that produce bacteriocins . Origins: environmental, animal and human sources . E. faecalis: . most common in the gastrointestinal tract, and may be found in human and animal faeces . associated with clinical urinary tract infections, hepatobiliary sepsis, endocarditis, surgical wound infection, bacteraemia and neonatal sepsis . able to survive a range of adverse environments allowing multiple routes of cross- contamination . resistant to a broad range of antibiotics including ampicillin, ciprofloxacin and imipenem ANTIBIOTICS NATURALLY OCCURING -
GBS 10 Strep11 Other 60 Vaginal Swabs! Real-Time LAMP!
• Specificity studies were performed using a panel of 10 Group B Streptococcus agalactiae strains, 11 of the most commonly occurring Streptococcus genus strains and 60 other organisms commonly found in the human genital tract. • One hundred and twenty four (124) vaginal swabs sampled from pregnant women were tested with the real-time LAMP assay and compared to a real- time PCR assay (5). Neonatal infections are most commonly caused by Group B Streptococcus GBS 10 (Streptococcus agalactiae) (1). These infections can be classified as either early on-set • Of the 124 vaginal swabs, 85 tested positive for Group B Streptococcus and & or late-onset disease. Early onset infection (EOI) occurs during the first week of life 39 tested negative. with late onset infection (LOI) occurring between one week and three months. It is Strep11 thought that early onset disease develops in the foetus after aspiration of infected • Comparable results were achieved by both the real-time PCR and real –time amniotic fluid (2). Late onset infection is less well understood, and while passage LAMP assays. Results are listed in Table 4. Also shown in the table are through the birth canal is an obvious route of infection, it is also thought that community previously obtained microbiological culture data for the isolation and sources are involved (2). Other identification of GBS. 60 One approach used to identify potential for infection is a screening of pregnant women, where prophylaxis is offered to those identified as carriers (3). This approach is also • Figure 1: Breakdown of specificity panels investigated during the development of the Table 2: Results of GBS testing of vaginal swabs.